Streetbeat News

Products Services

NTNX

WIT

Wipro has expanded its partnership with Nutanix to launch a new business unit aimed at accelerating digital transformation and hybrid multicloud innovation for their mutual clients.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:07 pm

HUGE

FSD Pharma announced the submission of a clinical trial application for a Phase-1b trial, METAL-1, to assess the safety and efficacy of Unbuzzd in healthy volunteers under alcohol intoxication. The application has been submitted for ethics review in Australia, with volunteer recruitment expected to start in April pending approval.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:07 pm

LCTX

Lineage Cell Therapeutics, Inc. (LCTX) announced that preclinical results for OpRegen will be presented at the 2024 ARVO meeting. OpRegen, developed in collaboration with Roche and Genentech, is a treatment for geographic atrophy secondary to age-related macular degeneration. The study shows OpRegen's engraftment in the retinal pigmented epithelium of mini-pigs, indicating potential benefits for retinal health and function. The presentation will highlight the survival and distribution of OpRegen post-administration.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:06 pm

J

Jacobs Solutions Inc (NYSE:J) and Mott MacDonald have been chosen by Thames Water to support the delivery of its $5.9 billion asset investment programs. This eight-year deal involves technical, engineering, and planning services for major water infrastructure projects in the UK. Jacobs recently reported a 9.5% YoY revenue growth and an adjusted EPS of $2.02 for the first quarter of FY24.

Portfolio Pulse from Lekha Gupta

March 11, 2024 | 12:05 pm

IMRX

Immuneering has initiated a Phase 2a clinical trial for IMM-1-104, targeting RAS-mutant solid tumors, marking a significant step in its development pipeline. The dosing of the first patient in this trial is a critical milestone for the company, potentially impacting its valuation and investor interest as it progresses through clinical stages.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:03 pm

BIVI

BioVie announced the completion of a funding round aimed at advancing its clinical priorities in Parkinson's Disease, Alzheimer's Disease, and Ascites/Liver Disease. The company is also exploring longevity and aging with partners.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:02 pm

ATXI

Avenue Therapeutics announced it will present preclinical data for BAER-101 at the American Society For Experimental Neurotherapeutics 2024 Annual Meeting on March 13. This marks a significant step in the development of BAER-101.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:01 pm

ARCT

Arcturus Therapeutics (NASDAQ:ARCT) has seen a variety of analyst ratings over the past three months, with a recent positive shift in sentiment. Four analysts have provided ratings, with the latest 12-month price targets showing an average of $63.25, up 14.31% from the previous $55.33. The company's financial performance has been strong, with significant revenue growth and above-average financial metrics compared to the industry. Arcturus focuses on RNA medicines for rare diseases, with a notable pipeline including LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 12:01 pm

BNTX

BioNTech announced it will present clinical data updates for its personalized mRNA-based and targeted oncology candidates at the AACR 2024 conference. This showcases the company's ongoing efforts in advancing its oncology pipeline.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:53 am

MLTX

MoonLake Immunotherapeutics' stock is trading higher following the announcement of positive 24-week data from the ARGO trial in psoriatic arthritis, along with other research and development updates.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:50 am